2023 Incentive Reminder from Highmark: Applies to Small Group & Large Group clients in PA, with effective dates 2/1/23 1/1/24
Monitoring requirements include assessment for signs of pancreatitis (persistent severe abdominal pain, often radiating to the back, with or without vomiting) and gallbladder disease (right upper quadrant pain, nausea, vomiting), both of which have been reported with GLP-1 receptor agonists
Consult Your Healthcare Team: Discuss exercise or supplementation plans with your healthcare provider to ensure safety and compatibility with GLP-1 medications
Although relatively small in scale, First-in-Human trials generate several key insights that guide later clinical development.
The frequency of your NAD+ infusions depends on your baseline depletion
The production of intrinsic factor happens in the stomach, which if impaired, can have a hard time properly synthesizing this protein